Search clinical trials for: Cholinergic Antagonists

Total 35838 results

Seoul National University Hospital

Unknown

Effect of Glycopyrrolate and Atropine on Catheter-Related Bladder Discomfort

Urinary Bladder Neoplasms | Anesthesia | Complications | Catheter Site Discomfort

Korea, Republic of
Jaeb Center for Health Research
National Eye Institute (NEI)

Completed

Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia

Amblyopia

United States
Jewish General Hospital
Centre de recherche du Centre hospitalier universitaire de Sherbrooke; Ottawa...

Completed

Efficacy of a Combined Surgical and Pharmacological Therapy to Treat Mixed Urinary Incontinence.

Urinary Incontinence Mixed (Stress and Urge)
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium

Chronic Obstructive Pulmonary Disease

Belgium, France, Japan
National Eye Institute (NEI)

Completed

Amblyopia (Lazy Eye) Treatment Study

Strabismus | Amblyopia | Anisometropia

United States
Markus KOSEL
University Hospital, Geneva; H. Lundbeck A/S; University Hospital, Basel, Switzerland and other collaborators

Terminated

EScitalopram PIndolol ONset of Action (ESPION)

Unipolar Depression

Switzerland
The Hong Kong Polytechnic University
The University of Hong Kong

Recruiting

Pharmacological and Non-pharmacological Treatment Effects on Children With Different Predicted Myopia Progression Rate

Myopia

Hong Kong
Ohio State University
University of California, Berkeley; Stanford University; University of Houston; Indiana University and other collaborators

Withdrawn

Delaying the Onset of Nearsightedness Until Treatment Study (DONUT)

Myopia
Belfast Health and Social Care Trust

Active, not recruiting

Low-dose Atropine Eye Drops to Reduce Progression of Myopia in Children in the United Kingdom (CHAMP-UK)

Myopia

United Kingdom
Scripps Health

Completed

Adverse Events Related to Low Dose Atropine (AELDA)

Myopia, Progressive

United States
Chiesi Farmaceutici S.p.A.

Completed

Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration (GLY2)

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
Cairo University

Completed

Effect Of Intravenous Hyoscine -N-Butyl Bromide In Management Of Prolonged Labor In Nulliparous

Prolonged Labor

Egypt
Orion Corporation, Orion Pharma

Completed

Absorption of Indacaterol and Glycopyrronium From Ultibro Breezhaler (FINDA)

Healthy Volunteers

Finland
James J. Peters Veterans Affairs Medical Center

Withdrawn

Use of High Resolution Colonic Manometry in Studying Motility

Gastrointestinal Dysfunction

United States
Vanderbilt University

Completed

Atropine in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Catecholaminergic Polymorphic Ventricular Tachycardia

United States
Kessler Foundation
National Institute on Disability, Independent Living, and Rehabilitation...

Unknown

Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury (MOSET-SCI)

Spinal Cord Injuries | Urinary Bladder, Neurogenic

United States
Novartis Pharmaceuticals

Completed

A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients

COPD

Korea, Republic of
Yonsei University

Terminated

Effect of Atropine or Glycopyrrolate on the Prevention of Bradycardia During Sedation Using Dexmedetomidine in Adult Patients Undergoing Lower Extremity Surgery Under Spinal Anesthesia

Spinal Anesthesia

Korea, Republic of
Astellas Pharma Europe Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment. (BEYOND)

Urologic Diseases | Urinary Bladder, Overactive | Urinary Bladder Diseases

Greece, Ireland, Armenia, Austria, Belarus, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Hungary, Italy, Kazakhstan, Latvia, Lebanon, Lithuania, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovaki... and more
Vanderbilt University Medical Center
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Pathophysiology of Cardiometabolic Risk Factors in African Americans

Hypertension | Obesity

United States
Novartis Pharmaceuticals

Withdrawn

Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients.

Pulmonary Disease, Chronic Obstructive
Hospital Clinic of Barcelona

Suspended

Role of Hyoscine Bromide in Latent and Active Labor

Labor, First Stage

Spain
University Hospital, Gentofte, Copenhagen
University of Copenhagen

Unknown

Atropin and Glucose Stimulated Insulinsecretion and the Cephalic Insulin Response

The Focus of This Study is to Evaluete the Significances of the Vagal Cholinerg Nervuos System for the Effect of GLP-1 by Using Atropin Administration.

Denmark
MicroDose Defense Products L.L.C.
University of Pittsburgh; U.S. Army Space and Missile Defense Command

Completed

A Study of Inhaled Atropine Sulfate in Healthy Adults

Organophosphorus Poisoning

United States
Centre de recherche du Centre hospitalier universitaire...

Recruiting

Impact in Older Adults of Reducing Anticholinergic and Sedative Rx Burden on Physical Function Measured by Wearables

Physical Function | Deprescribing Anticholinergic and Sedative Medications

Canada
Boehringer Ingelheim

Completed

Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Airways Disease

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways Disease

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Post-marketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive
Neutec Ar-Ge San ve Tic A.Ş

Completed

Comparison of 24 Hour Bronchodilator Efficacy of Tiotropium 18 mcg Delivered Via DISCAIR Versus SPIRIVA 18 µg Delivered Via HANDIHALER® in Patients With Moderate to Severe COPD

COPD
Orion Corporation, Orion Pharma

Completed

Effect of Charcoal on Gastrointestinal Absorption of Tiotropium (TIOBLOCK)

Healthy Volunteer Study

Finland
University Health Network, Toronto
Parkinson's Disease Foundation

Completed

Ipratropium Spray for Drooling Saliva in Parkinson's Disease

Parkinson's Disease

Canada
Hamilton Health Sciences Corporation

Unknown

Study of a Tiotropium Inhaler For Shortness of Breath in Advanced Non-Small Cell Lung Cancer (TIDAL)

NSCLC | Dyspnea

Canada
Boehringer Ingelheim

Completed

Actuation Indicator Trial in Patients With COPD

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim
Pfizer

Completed

Assessment of Health-status of Patients With Chronic Obstructive Pulmonary Disease (COPD) on Maintenance Therapy With Spiriva HH Measured by COPD Assessment Test (CAT) Test

Pulmonary Disease, Chronic Obstructive

Poland
Boehringer Ingelheim

Completed

Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Australia, Austria, Belgium, Brazil, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, Ireland, Italy, Japan, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Philip... and more
Boehringer Ingelheim

Completed

Tiotropium / Respimat One Year Study in COPD.

Pulmonary Disease, Chronic Obstructive

United States, Australia, Brazil, Canada, China, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Italy, Korea, Republic of, Lithuania, Malaysia, Mexico, Netherlands, Norway, Portugal, Singapore, Slovakia, South... and more
Boehringer Ingelheim

Completed

Pharmacokinetics of the Fixed Dose Combination of Tiotropium Plus BI 54903 Versus the Combination of the Monoproducts of Tiotropium and BI 54903 in Healthy Volunteers

Healthy

Germany
NHS Greater Glasgow and Clyde

Withdrawn

Replacement of Nebulised Ipratropium With Inhaled Tiotropium in Stable Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United Kingdom
Boehringer Ingelheim

Completed

Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data

Pulmonary Disease, Chronic Obstructive

China
The Taub Group

Completed

The Safety and Efficacy of Naltrexone and Scopolamine Utilized in the Treatment of Major Depression

Depression

United States
Michael E. Chua
St. Luke's Medical Center, Philippines

Completed

Efficacy and Safety of Gabapentin in Treating Overactive Bladder (OAB)

Quality of Life | Nocturia | Incontinence | Urinary Urgency | Urinary Frequency | Detrusor Uninhibited Activity

Philippines
Elpen Pharmaceutical Co. Inc.

Not yet recruiting

QualiTy of Life Evaluation in Patients With ChRonic ObstructIve Pulmonary Disease Who Require Tiotropium as additiOnal treatmeNt. (TRITON)

COPD
State University of New York at Buffalo
National Center for Advancing Translational Sciences (NCATS)

Completed

Defining and Treating Depression-related Asthma

Depression | Asthma | Childhood Asthma

United States
MetroHealth Medical Center
Sunovion

Completed

A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation

Asthma

United States
Boehringer Ingelheim

Completed

Characteristics of Pts Initiating Spiriva Respimat in Asthma

Asthma

Germany
GlaxoSmithKline

Completed

GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Germany, United States
GlaxoSmithKline

Completed

A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD) (AC4115321)

Pulmonary Disease, Chronic Obstructive

United States
3M

Completed

Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With Reference

Healthy
Boehringer Ingelheim

Completed

A Collection of Vital Status and Pulmonary Medication Usage Data for Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Withdrew Prematurely From Tiotropium Inhalation Solution Delivered by the Respimat Inhaler

Pulmonary Disease, Chronic Obstructive

Australia, New Zealand, United Kingdom
Boehringer Ingelheim

Completed

Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection

Pulmonary Disease, Chronic Obstructive

United States

Search clinical trials for: Cholinergic Antagonists

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations